Romazarit

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2R)-2-[[4-(2,4-dioxothiazolidin-3-yl)phenyl]methyl]-3-methylbutanoic acid | image = Romazarit_structure.png | width = 200 | CAS_number = 87679-37-6 | ATC_prefix = M01 | ATC_suffix = AX06 | PubChem = 65659 | ChemSpiderID = 59095 | UNII = 3F0I0T7Y6P | KEGG = D05792 | ChEMBL = 2103880 | C=15 | H=17 | N=1 | O=4 | S=1 | smiles = CC(C)C(C(=O)O)Cc1ccc(cc1)C2C(=O)NC(=O)S2 | StdInChI = 1S/C15H17NO4S/c1-8(2)12(15(18)19)7-10-3-5-11(6-4-10)9-13-14(17)16-15(20)21-13/h3-6,8,12H,7,9H2,1-2H3,(H,18,19)(H,16,17,20) | StdInChIKey = ZQZQYVZQXGQXQK-UHFFFAOYSA-N }}

Romazarit is a pharmaceutical compound that was investigated for its potential use in the treatment of rheumatoid arthritis. It belongs to a class of drugs known as disease-modifying antirheumatic drugs (DMARDs), which are used to slow the progression of rheumatoid arthritis and improve quality of life for patients.

Mechanism of Action

Romazarit is believed to exert its effects by modulating the immune response and reducing inflammation. The exact mechanism of action is not fully understood, but it is thought to involve the inhibition of certain cytokines and enzymes that play a role in the inflammatory process associated with rheumatoid arthritis.

Clinical Trials

Romazarit underwent several clinical trials to evaluate its efficacy and safety in patients with rheumatoid arthritis. Early studies suggested that Romazarit could reduce joint inflammation and slow disease progression. However, subsequent trials failed to demonstrate significant clinical benefits over existing treatments, leading to a decline in its development and use.

Side Effects

The side effects of Romazarit were similar to those of other DMARDs, including gastrointestinal disturbances, liver enzyme abnormalities, and potential hematological effects. Due to these side effects and the lack of superior efficacy, Romazarit was not widely adopted in clinical practice.

Current Status

As of the latest updates, Romazarit is not actively marketed or used in the treatment of rheumatoid arthritis. Research and development have shifted towards other more promising therapies that offer better efficacy and safety profiles.

Also see

• Rheumatoid arthritis
• Disease-modifying antirheumatic drugs
• Cytokine inhibitors
• Nonsteroidal anti-inflammatory drugs

Rheumatologic diseases

Arthritis is often used to refer to any disorder that affects the joints. Rheumatic diseases usually affect joints, tendons, ligaments, bones, and muscles. Rheumatologic diseases usually affect joints, tendons, ligaments, bones, and muscles.

Connective Tissue Diseases

Rheumatology and	Connective Tissue Diseases
Ankylosing spondylitis	Arthritis
Arthritis and Rheumatic diseases	Autoimmune diseases
Autoinflammatory diseases	Behçet’s disease
Bursitis	Giant cell arteritis
Gout	Juvenile arthritis
Knee problems	Lupus
Osteoarthritis	Polymyalgia rheumatica
Psoriatic arthritis	Reactive arthritis
Rheumatoid arthritis	Scleroderma
Sjögren’s syndrome	Systemic lupus erythematosus (Lupus)
Tendinitis	Rheumatologic diseases